Narrow-moat Coloplast COLO B kicked off its new fiscal year in strong fashion, despite diminishing ripple effects from the pandemic, and we’re leaving our fair value estimate unchanged. Quarterly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback